Category

Investing

Category

The 2024 manganese market was impacted by several factors including growing demand for battery applications, geopolitical risks, production disruptions and strategic investments.

Positive demand from the electric vehicle sector offered support as automakers increasingly turned to manganese-rich lithium-ion chemistries like lithium manganese iron phosphate (LMFP) to cut costs and reduce reliance on nickel and cobalt.

Meanwhile, supply chain vulnerabilities emerged due to political instability in major producing regions and heightened environmental scrutiny. In response, nations such as the US and Australia accelerated investments in refining facilities to reduce dependence on China and secure their EV battery supply chains.

Later in the year oversupply stemming from weaker than expected Chinese steel demand muted price growth in the space.

“Manganese sulphate prices turned bearish in Q4 … with slow spot buying in China and the effects of weather-related mine supply disruptions in Australia,” a Fastmarkets report from December reads.

Despite these challenges, the metals pricing firm foresees a recovery in the manganese market in the years ahead.

“We expect demand to grow from now and into the 2030s, driven in part by new chemistries like LMFP,” the firm notes. In the short to mid-term, China’s supply base looks set to fulfil global needs of high purity manganese, though there is likely to be a long-term need for a greater high purity manganese capacity.”

2024 trends: Supply disruption

Recounting the most impactful trends in the 2024 manganese market Clare Hanna, senior steel analyst at CRU pointed to several factors.

“The key drivers in 2024 were the outage at South32’s (ASX:S32,OTC Pink:SHTLF)Groote Eylandt mine, the surge in alternative supplies and the weak state of Chinese demand,” she said.

“This led prices to first rise very sharply and then plummet as the market oversupply became apparent.”

South32 — the world’s largest manganese producer — saw operations suspended at its Australia-based Groote Eylandt mine in March due to a tropical cyclone. A phased return to mining began in June 2024, however the severity of flooding due to the cyclone has impacted a wharf and the company’s ability to export.

In a statement, South32 said it expects exports to resume in Q3 2025.

Some of this reduced 2024 output was offset by purchase declines in China. As Hanna explained, Chinese demand was weak due to lower demand for steel rebar which was driven by weakness of the Chinese real estate sector.

Prices for manganese ore could face headwinds in the year ahead as South32 continues to ramp up Groote Eylandt.

“The return of South32 to the market and the increase in high-grade supply could be a challenge, given the Chinese real estate market is not expected to improve significantly. Steel demand and production in other markets is forecast to improve,” said Hanna.

Key demand drivers for 2025

Prized for their high energy density, automakers are increasingly turning to manganese-based batteries for their cost-effectiveness and reduced reliance on expensive metals like nickel and cobalt.

Although, as Hanna pointed out, the majority of manganese demand is still attributed to the steel sector.

“There is a lot of noise in the market about manganese usage in EV batteries, driven in part by companies looking for finance, and also because downstream, the processing of manganese ore for battery grade manganese products is heavily concentrated in China at the moment,’ she said. “However, it is worth recognising that in terms of manganese ore demand, the share that is going into EV supply chains is very small.”

The senior analyst went on to note that those dynamics are likely to shift in the coming years.

“While [EV sector] volume is growing and the demand from the steel sector is likely to decline over time, demand from steel supply chains will remain the dominant source of manganese ore demand, and therefore the biggest demand side influence on manganese ore prices,” said Hanna.

She went on to explain why the smaller EV market need has dominated the manganese narrative.

“When looking for investment, companies like to align their projects with growing market sectors, so when companies are talking about new mine investments, they often reference the EV supply chain, even if in practice, most of the ore will likely go to ferroalloy producers for consumption in steel production.”

Supply diversification

Like so many of the battery metals, the manganese supply chain is dominated by China, a factor many western nations are trying to grapple with. In an effort to bolster supply outside of China significant investments were made in 2024.

“What we are seeing is a number of projects aimed to produce High Purity Manganese Sulphate (HPMSM) outside of China to reduce OEM EV battery supply chain risk or take advantage of the benefits of the Inflation Reduction Act. Some of these are aligned with new or existing upstream mines,” said Hanna.

Despite the plan looking good on paper, the CRU steel specialist pointed out the challenges with building HPMSM supply independent of China.

“While some have pilot plants (some very small), operational plants are still at minimum, a couple of years off,” Hanna said.

She continued: “Production of HPMSM is a chemical process so existing producers of manganese metal or other manganese chemicals would be able to move into this product area more easily than ferroalloy producers, although there are still a lot of technical challenges. There are no ferroalloy producers, outside of China, moving to produce HPMSM.”

Some of those projects in the pipeline include the Manganese Metal Company’s HPMSM Metal to Crystal project in South Africa. Described as a more sustainable process, the Metal to Crystal production method will start with a 5,000 metric ton per annum plant in 2028, followed by a ~30,000 metric ton per annum plant, targeted beyond 2030.

Hanna also referenced South32’s US-based Hermosa project which received a US$20 million grant from the US Department of Defense in May 2024. The monies have been earmarked for the acceleration of domestic production of battery grade manganese.

Manganese processing plants have also attracted US government funding.

In September, Element 25 (ASX:E25:OTCQX:ELMT) secured a US$166 million grant from the US Department of Energy (DoE) under the Battery Materials Processing Grant Program.

The funding infusion will support the construction of E25’s HPMSM facility in Louisiana. The grant is in addition to US$115 million in funding already secured from offtake partners General Motors (NYSE:GM) and Stellantis (NYSE:STLA).

The feedstock for the Louisiana plant will originate from Element 25’s Butcherbird mine in Australia. In November, the company released a new resource estimate for the planned expansion at Butcherbird.

According to the company, the new estimate registers a 142 percent increase in measured and indicated resources, which now total 130 million tonnes at 10.23 percent manganese. Additionally, the site hosts a total resource of 274 million tonnes at 10 percent manganese.

Other notable companies Hanna referenced include: Euro Manganese (TSXV:EMN,OTCQB:EUMNF), which is developing a project in Czech Republic using manganese from old mine tailings, and also looking at plans for a plant in Quebec, Canada.

“Firebird Metals (ASX:FRB,OTC Pink:FRBMF) (in) Australia, has adopted an alternative approach,” she said. “They are partnering with a Chinese group to build an HPMSM plant in China, which could eventually be supplied with ore from an Australian mine.”

Trends to watch

While these supply chain diversification efforts aim to secure and steady output, Hanna warned of some trends to watch in 2025. Top of mind is South32’s Groote Eylandt mine and its ability to restart shipments this year.

In South Africa, she highlighted national rail operator Transnet’s plans for expansion.

“Transnet’s plans for the new port and rail infrastructure at Coega in South Africa are still some way off,” said Hanna. “The company’s performance on the existing rail network and ability to open up the routes beyond traditional miners will influence how much ore needs to be moved via the higher cost rail route.”

plans remain distant, while inefficiencies in the existing rail network could raise transport costs. Gabon’s production expansion in Moanda faces delays due to weak demand, compounded by past disruptions from railway landslides. In Ukraine, war-related damage to production and demand persists, with recovery dependent on potential ceasefire agreements.

Manganese producer Eramet (EPA:ERA), has also faced challenges to its production expansion plans at the Moanda project in Gabon.

“These [plans] were slowed in Q4 by weak demand,” she said. “Work continues on improvements to the Trans Gabon Railway. Landslides and derailments in the past have disrupted supply causing ore price volatility.”

A resolution to the war in Ukraine could also serve as a catalyst to the 2025 supply and demand story.

“Historically Ukraine was a significant producer and consumer of manganese alloys. Both have been slowed by the war. In the event of a ceasefire this year, supply is likely to return faster than demand as the large Mauripol steel plant was destroyed during the Russian invasion,” she added.

According to Hanna, key areas to watch as the year progresses are trade actions and carbon taxes. These include the US investigation into ferrosilicon imports from several countries, paired with the incoming Trump administration may signal broader tariffs.

Elsewhere, the EU’s probe into manganese alloys and ferrosilicon may raise regional prices

“The EU Carbon Border Adjustment Mechanism is due to come in at the beginning of 2026. Ferromanganese is covered, silicomanganese is not,’ said Hanna. “There is a lot of uncertainty about the impact of this.”

Securities Disclosure: I, Georgia Williams, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Stock Trend Capital Inc. (CSE: PUMP) (FSE: P0G) (PTC Pink: STOCF) (the ‘Company’ or ‘Stock Trend’) announces that the Company has entered into a loan agreement (the ‘Loan Agreement’) dated January 7, 2025, with 1001070426 Ontario Inc. dba eGOD Digital Labs (‘eGod’ or ‘the ‘Borrower’), whereby the Company has agreed to provide the Borrower with a loan in the amount of $1,000,000 (the ‘Loan’). The Loan is to support the Borrower’s strategic initiatives and business operations.

The Loan: (i) accrues interest on the loan amount at a rate equal to 10% per annum; (ii) matures on June 30, 2026 (the ‘Maturity Date’); and (iii) is secured by first-priority security interest on the personal property of the Borrower, pursuant to a general security agreement.

In connection with the Loan, the Borrower agreed to issue to the Company an anti-dilution warrant (the ‘Anti-Dilution Warrant’), which entitles the Company to exercise the warrant to 25% of the Borrower for nominal consideration. The Borrower also agreed to pay Stock Trend a royalty in the amount of 7% of the revenue generated by the Borrower until a total amount of royalty of $500,000 has been paid to the Company (the ‘Royalty’). In addition, the Company has the right to elect to convert all or part of the Loan, together with any accrued interest and including the full Royalty entitlement, into fully-paid and non-assessable common shares of eGod, which if exercised by the Company may result in the Company owning more than 51% of the Borrower, inclusive of an exercise of the Anti-Dilution Warrant.

We are excited to provide this financial support to eGod Digital Labs and look forward to fostering the growth and success of their operations,’ said Anthony Durkacz, Chief Executive Officer and Chairman of Stock Trend Capital, ‘This agreement underscores our commitment to investing in high-potential opportunities while ensuring value for our shareholders through robust protections like anti-dilution warrants and royalty payments.’

About eGOD Digital Labs

eGOD Digital Labs is focused on becoming a leader in the Dogecoin and Litecoin mining space. eGOD is dedicated to building sustainable, efficient, and scalable solutions that strengthen these networks. By leveraging advanced mining systems, eGOD aims to support the long-term growth and potential of Dogecoin and Litecoin. For additional information please visit www.egoddigital.com.

About Stock Trend

Stock Trend Capital Inc. is an investment issuer primarily focused on the AI sector, crypto sector, and the Canadian cannabis industry. The issuer intends to focus on investing in private and public entities with strong intellectual property, exceptional management and high growth potential that may be strategically positioned in the market.

On behalf of the Board of Directors of
STOCK TREND CAPITAL INC.

FOR FURTHER INFORMATION, PLEASE CONTACT:
Anthony Durkacz
CEO, Director
Telephone: (416) 720-4360
Email: anthony@stocktrend.com

Cautionary Note Regarding Forward-Looking Statements

This news release contains ‘forward-looking statements’ within the meaning of applicable securities laws. Forward-looking statements are based on the opinions, assumptions, factors and estimates of management considered reasonable at the date the statements are made. The opinions, assumptions, factors and estimates which may prove to be incorrect.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information. Such risks and other factors include, among others: general economic, market, or business conditions; uninsured risks; regulatory changes; and other risks detailed herein and from time to time in the filings made by the Company with securities regulators. Although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ from those described in forward-looking statements, there may be other factors that cause such actions, events, or results to differ materially from those anticipated. There can be no assurance that forward-looking statements will prove to be accurate and accordingly readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking information in this news release may include statements about the completion of the Loan, the terms of the Loan, the use of proceeds from the Loan, and statements regarding management’s expectations on the Company’s future performance among other statements.

The statements in this press release are made as of the date of this release. Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Source

This post appeared first on investingnews.com

Cryptocurrencies such as Bitcoin and Ethereum offer an alternative route for building and storing wealth. While directly holding these digital assets is a popular option, investors are also clamoring for financial products such as crypto exchange-traded funds (ETFs).

Canada first launched Bitcoin and Ethereum ETFs in 2021. These Canadian Bitcoin and Ethereum ETFs allow investors to place returns in tax-sheltered accounts like tax-free savings accounts or registered retirement savings plans.

“There is a high demand for a Bitcoin product that has all the features that people love about ETFs — that they trade on an exchange, that they’re liquid,” Ross Mayfield, investment strategy analyst at Robert W. Baird & Co., told Bloomberg in mid-2021.

Interest has only increased since then. In the US, Bitcoin ETFs’ net assets surpassed US$100 billion on November 21, gaining ground on US gold ETFs. Sean Farrell, head of digital asset strategy at Fundstrat, wrote in mid-2023 that the Bitcoin ETF category at large has the potential to surpass the precious metals ETF market in terms of asset value. ‘Bitcoin ETF eventually could become >$300 billion category,’ he stated in the note.

Ethereum ETFs have also become a major talking point. Ethereum is the most widely used blockchain technology, and Ether, the digital currency of this platform, is the second largest cryptocurrency after Bitcoin.

With that in mind, it’s worth taking a look at the currently available Canadian cryptocurrency ETFs. The list below includes 13 Ether and Bitcoin ETFs available on the Canadian market sorted by assets under management, and all data presented is current as of January 14, 2025.

1. Purpose Bitcoin ETF (TSX:BTCC)

Company Profile

Assets under management: C$3.1 billion

Billed as the world’s first physically settled Bitcoin ETF, the Purpose Bitcoin ETF launched in February 2021 and is backed by Bitcoin in cold storage. This means the fund allows investors to add and sell Bitcoin with no digital wallet required.

Hosted by Canadian investment company Purpose Investments, the Purpose Bitcoin ETF is backed by 25610.96 Bitcoins and has a management expense ratio of 1 percent.

2. CI Galaxy Bitcoin ETF (TSX:BTCX.B)

Company Profile

Assets under management: C$1.23 billion

Launched in March 2021, the CI Galaxy Bitcoin ETF was born out of a partnership between cryptocurrency leaders Galaxy Fund Management and CI Global Asset Management. Galaxy Fund Management is part of Galaxy Digital, a diversified financial services firm with a focus on digital assets and the blockchain technology sector.

The ETF’s objective is to give investors exposure to Bitcoin via an institutional-quality fund platform, as its holdings are wholly Bitcoin and are kept in cold storage. At 0.4 percent, this fund boasts one of the lowest management fees of all the crypto funds on the market.

3. Fidelity Advantage Bitcoin ETF (TSX:FBTC)

Company Profile

Assets under management: C$1.02 billion

The newest Bitcoin fund on this list, the Fidelity Advantage Bitcoin ETF, launched in November 2021. It offers the security of Fidelity’s in-house cold storage services for its holdings.

While it previously had a management fee of 0.4 percent, in line with the CI and Galaxy funds, the Fidelity Advantage Bitcoin ETF lowered it in January 2024 to an ultra-low management fee of 0.39 percent.

4. CI Galaxy Ethereum ETF (TSX:ETHX.B)

Company Profile

Assets under management: C$554.78 million

The CI Galaxy Ethereum ETF, another collaboration between CI and Galaxy, offers investors exposure to the spot Ethereum price through Ether holdings in cold storage. The fund launched on April 20, 2021, the same day as two of the other Ether ETFs on this list.

At the time, CI Global Asset Management suggested that “owning Ether is similar to owning a basket of early-stage, high-growth technology stocks.”

The CI Galaxy Ethereum ETF has notably low management fees of just 0.4 percent.

5. Purpose Ether ETF (TSX:ETHH)

Company Profile

Assets under management: C$410.3 million

The Purpose Ether ETF is a direct-custody Ether ETF that launched on April 20, 2021. This fund holds 94065.95 Ether, which it stores in cold storage.

The Purpose Ether ETF offers investors exposure to the daily price movements of physically settled Ether tokens with a management fee of 1 percent.

6. 3iQ CoinShares Bitcoin ETF (TSX:BTCQ)

Company Profile

Net asset value: C$342.9 million

Launched in March 2021, the 3iQ CoinShares Bitcoin ETF offers exposure to the price movement of Bitcoin in US dollar terms. The company holds its Bitcoin assets in cold storage. This ETF has a management fee of 1 percent.

7. Evolve Bitcoin ETF (TSX:EBIT)

Company Profile

Assets under management: C$270.42 million

Evolve ETFs partnered with cryptocurrency experts, including Gemini Trust Company, CF Benchmarks, Cidel Bank & Trust and CIBC Mellon Global Services, to launch the Evolve Bitcoin ETF. The fund, which holds its own Bitcoin, has a management fee of 0.75 percent.

Launched a week after the Purpose Bitcoin ETF, its holdings of Bitcoin are priced based on the CME CF Bitcoin Reference Rate, a once-a-day benchmark index price for Bitcoin denominated in US dollars.

8. Purpose Bitcoin Yield ETF (TSX:BTCY)

Company Profile

Assets under management: C$150 million

The Purpose Bitcoin Yield ETF uses a covered call strategy to generate yield for investors, which involves writing call options on Bitcoin. Call options give the buyer an option to purchase an asset at a specific price on or before a specific date.

Its structure allows the fund to earn income from option premiums while providing investors with exposure to Bitcoin’s price movements. Its distributions are paid monthly.

9. 3iQ CoinShares Ether Staking ETF (TSX:ETHQ)

Company Profile

Net asset value: C$‪103.92 million

Following the success of its Bitcoin ETF, 3iQ Digital Asset Management launched its CoinShares Ether Staking ETF in April 2021. This fund has a similar objective, offering exposure to Ether and its daily US dollar price movements. It also has a management fee of 1 percent.

10. Evolve Ether ETF (TSX:ETHR)

Company Profile

Assets under management: C$80.23 million

The Evolve Ether ETF offers investors an easier route to investing directly in Ether. The fund’s holdings of Ether are priced based on the CME CF Ether-Dollar Reference Rate, a once-a-day benchmark index price for Ether denominated in US dollars. As with the Evolve Bitcoin ETF, the Evolve Ether ETF has a management fee of 0.75 percent.

11. Evolve Cryptocurrencies ETF (TSX:ETC)

Company Profile

Assets under management: C$75.68 million

The Evolve Cryptocurrencies ETF launched in September 2021 as the first multi-cryptocurrency ETF, providing combined exposure to both Bitcoin and Ether.

This product from Evolve ETFs allows investors to diversify their crypto portfolios and provides indirect exposure to the two coins, weighing them by market capitalization and rebalancing its holdings on a monthly basis. Bitcoin makes up the majority of its portfolio.

While this ETF has no management fee, the underlying funds that hold both Bitcoin and Ether have management fees of 0.75 percent plus applicable taxes.

12. Purpose Ether Yield ETF (TSX:ETHY)

Company Profile

Assets under management: C$69.3 million

Like the Purpose Bitcoin Yield ETF, the Purpose Ether Yield ETF offers investors an opportunity to invest in Ether while also generating yield. Purpose Investments lends a portion of its Ether holdings to institutional borrowers and earns interest on those loans.

Investors who purchase shares of this ETF receive a portion of the interest earned in monthly distributions.

13. Fidelity Advantage Ether ETF (TSX:FETH)

Company Profile

Assets under management: C$47.6 million

Following the successful launch of its Bitcoin fund, Fidelity brought its Advantage Ether ETF to market in September 2022, making this the newest Ether ETF in Canada. Its holdings are stored in Fidelity’s in-house cold storage.

The Fidelity Advantage Ether ETF has a management fee of 0.4 percent.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Zinc prices gained more than 16 percent in 2024. While the metal’s value has trended down in the first week of the new year in 2025, experts agree zinc’s long-term fundamentals are healthy.

Many base metals have been hit by weakened demand in recent years due to sticky inflation and higher interest rates, and zinc is no exception. Zinc supply has also faced pressure from higher mining and refining costs, causing some major zinc mines and smelters to suspend operations, with more possible if the current economic situation continues. Once demand rebounds along with the economy, stunted demand may once again push zinc prices higher.

Data was gathered on January 10, 2025, using TradingView’s stock screener, and only zinc stocks with market caps greater than C$50 million at that time were considered. Read on to learn more about their operations and plans.

1. Teck Resources (TSX:TECK.A,TSX:TECK.B)

Company Profile

Market cap: C$31.79 billion
Share price: C$60.87

Teck Resources is a major global polymetallic mining company, as well as one of the top zinc producers in the world. It produced 644,000 metric tons (MT) of zinc in concentrate in 2023, with 539,800 MT coming from its Red Dog zinc mine in Alaska. The remaining 104,200 MT came from Teck’s 22.5 percent share of zinc production from the Antamina copper-zinc mine in Peru.

Total production guidance for 2024 is set in a range of 565,000 MT to 630,000 MT. As of September 30, 2024, Teck’s zinc production for the year totaled 551,000 MT.

The company also owns the Trail operations, which it describes as ‘one of the world’s largest fully integrated zinc and lead smelting and refining complexes.’ Located in BC, Canada, the Trail operations produced 266,600 MT of refined zinc in 2023, with 240,000 to 250,000 MT of the material expected in 2024.

The Trail operations was the first standalone zinc-processing site to receive the Zinc Mark verification. ‘To achieve the Zinc Mark, Teck’s Trail Operations was assessed and independently verified against 32 responsible production criteria including greenhouse gas emissions, community health and safety, respect for Indigenous rights and business integrity,’ the company explained in a press release in 2023. In February 2024, the Red Dog mine also earned the Zinc Mark for environmentally and socially responsible production practices.

Teck pays a quarterly dividend to its shareholders. On December 31, the company paid out a dividend of C$0.125 per share.

2. Emerita Resources (TSXV:EMO)

Press ReleasesCompany Profile

Market cap: C$287.97 million
Share price: C$1.14

Emerita Resources has a portfolio of high-grade, large-scale polymetallic projects covering more than 26,000 combined hectares in Spain’s Iberian Pyrite Belt. The company’s flagship asset is the Iberian Belt West project, which hosts three massive sulfide deposits: La Infanta, La Romanera and El Cura.

Emerita released a mineral resource estimate for Iberian Belt West in May 2023. It finished environmental baseline studies the following month, and completed the required supporting documentation for its mining license application in December.

As for its work in 2024, the company released Phase 2 metallurgical testing results for the La Romanera and La Infanta deposits in October. The results demonstrate that commercial-grade copper, lead and zinc concentrates can be obtained from both deposits.

Drilling is underway at the El Cura deposit to establish a mineral resource estimate with test work to follow. In July, the Andalusian government granted Iberian Belt West a declaration of strategic interest, which will streamline the process of moving the project through development. Results released in early December showed that drilling at La Cura intersected 13.15 meters in massive sulfides grading 3.3 percent zinc, 1.1 percent copper and 1.1 percent lead.

3. Fireweed Metals (TSXV:FWZ)

Press ReleasesCompany Profile

Market cap: C$263.32 million
Share price: C$1.44

Fireweed Metals is a critical metals company whose flagship Macmillan Pass zinc project is located in Canada’s Yukon. In 2023, the company acquired the Gayna River zinc project in the Northwest Territories and the Mactung tungsten project, which is adjacent to Macmillan Pass and straddles the border between Yukon and the Northwest Territories. According to the company’s website, Mactung ‘hosts the world’s largest high-grade tungsten deposit.’

Even with these new assets, the company still has a strong focus on Macmillan Pass. In fact, in November 2023, the Fireweed team, led by Dr. Jack Milton, the firm’s vice president of geology, received the 2023 Association for Mineral Exploration H.H. “Spud” Huestis Award for its work at the Macmillan Pass property.

Fireweed’s best drill intersection to date from Macmillan Pass’ Boundary zone includes 143.95 meters true width at 14.45 percent zinc, including 28.71 meters at 25.52 percent zinc. In June 2024, the company launched a 14,000 meter summer drill program, billed as the largest regional exploration campaign ever at Macmillan Pass. Subsequently, in September it released an updated mineral resource estimate for the Tom and Jason deposits, as well as the inaugural resource estimates for the Boundary Zone and End Zone deposits at the project.

4. Trilogy Metals (TSX:TMQ)

Company Profile

Market cap: C$246.18 million
Share price: C$1.57

Trilogy Metals is focused primarily on copper, zinc and cobalt at its Alaskan Upper Kobuk projects, which are held by Ambler Metals, a joint venture operating company owned equally by Trilogy and South32 (ASX:S32,OTC Pink:SHTLF).

Its most advanced zinc project is the Arctic copper-zinc-lead-gold-silver volcanogenic massive sulfide project, which is in the feasibility stage and has proven and probable reserves of 43.44 million MT grading 3.12 percent zinc.

In addition, early-stage field work at the company’s wholly owned Helpmejack project in Alaska’s Ambler Schist Belt outlined two target areas prospective for volcanogenic massive sulfide and shale-hosted zinc deposits.

Trilogy had been focusing on improving access to the region with its Amber Access project, but it was rejected by the US Bureau of Land Management in June 2024 due to the impact the proposed road would have on the environment and communities in the region, which has seen little development.

Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Biotech is a dynamic industry that is driving scientific advancements and innovation in healthcare. In Canada, the biotech industry is home to companies pursuing cutting-edge therapies and medical technologies.

According to Grandview Research, the global biotech market is expected to grow at a CAGR of 13.96 percent between 2024 and 2030 to reach a value of US$3.08 trillion.

Data on Canadian biotech stocks was collected on January 14, 2024, using TradingView’s stock screener. Only companies with market capitalizations of over C$50 million at that time were considered. Companies on the TSX, TSXV and CSE were considered, but no TSXV-listed stocks made the list this time. Read on to learn what’s been driving these biotech firms.

1. Bright Minds Biosciences (CSE:DRUG)

Press ReleasesCompany Profile

Year-on-year gain: 2,131 percent
Market cap: C$391.38 million
Share price: C$56.00

Bright Minds Biosciences is focused on developing novel treatments for neuropsychiatric disorders and pain. Its portfolio consists of serotonin agonists designed to target neurocircuit abnormalities that make disorders like epilepsy, post-traumatic stress disorder and depression difficult to treat.

The company’s drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds such as psilocybin.

Bright Minds is in Phase 2 clinical trials of its candidate BMB-101 in patients with classic absence epilepsy and developmental epileptic encephalopathy.

On October 15, the company’s stock price surged nearly 1,500 percent in a single session. While Bright Minds didn’t have news of its own, the move was likely influenced by global pharmaceutical company Lundbeck’s announcement of intention to acquire Longboard Pharmaceuticals, which has a similar drug candidate. Bright Minds closed a non-brokered private placement that included participation from a group of healthcare investors on November 4, 2024.

2. ME Therapeutics Holdings (CSE:METX)

Company Profile

Year-on-year gain: 369.42 percent
Market cap: C$95.72 million
Share price: C$5.68

ME Therapeutics Holdings is a biotechnology company focused on developing cancer-fighting drug candidates that can increase the efficacy of current immuno-oncology drugs by targeting suppressive myeloid cells, which have been found to hinder the effectiveness of existing immuno-oncology treatments. Immuno-oncology is a relatively new area of cancer drug research and has shown promising results when used to treat cancer with low survival rates.

In December 2023, the company shared research done in collaboration with Dr. Kenneth Harder at the University of British Columbia suggesting ME Therapeutics’ antibody, h1B11-12, successfully blocks a protein that fuels breast and colon cancer growth (G-CSF). Trial planning efforts are ongoing, and the company expects development of a cell line for future production of the drug to be finished in the latter half of 2025.

In addition, the company is part of an ongoing collaborative effort to develop therapeutic MRNA delivery methods to myeloid cells with NanoVation Therapeutics, a biotech company that develops customized nucleic acid and lipid nanoparticle technologies to empower genetic medicine. The collaboration has already resulted in two new MRNA formulations, for which testing began on October 4.

3. Medicenna (TSX:MDNA)

Company Profile

Year-on-year gain: 217.07 percent
Market cap: C$104.81 million
Share price: C$1.30

Medicenna is a clinical-stage immuno-oncology company specializing in the development of innovative therapies for patients with challenging unmet needs. Its focus is on creating novel, highly selective versions of cytokines — small proteins that play a crucial role in regulating immune responses — such as IL-2, IL-4 and IL-13, which it refers to as ‘Superkines’ and ’empowered superkines.’

Interleukins, which Medicenna says are at the core of its therapies, are groups of cytokines. The company’s interleukins are engineered to fuse with specific molecules to optimize their function. Its therapies treat solid tumors, which have a low response rate to conventional cancer treatments, and autoimmune and neuroinflammatory diseases.

Medicenna’s lead candidate, MDNA11, has demonstrated therapeutic activity and an acceptable safety profile during clinical trials of monotherapy dose escalation in treating patients with advanced solid tumors.

On December 5, the company shared a clinical update for its Phase 1/2 ABILITY-1 study, which is testing MDNA11 in combination with Merck’s KEYTRUDA, revealing one patient in the study had a complete response after receiving eight weeks of treatment.

4. Cardiol Therapeutics (TSX:CRDL)

Press ReleasesCompany Profile

Year-on-year gain: 27.86 percent
Market cap: C$149.33 million
Share price: C$1.79

Cardiol Therapeutics is a biopharma company developing innovative treatments for inflammation and fibrosis in cardiovascular conditions. Its research is concentrated on pericarditis, which is inflammation of the membrane surrounding the heart; myocarditis, or inflammation of the heart muscle; and heart failure.

Cardiol currently has two drug candidates in its pipeline. CardiolRx, the company’s lead candidate, received an orphan drug destination in February 2024.

Cardol shared the results of its Phase 2 open-label pilot study of CardiolRx in patients with symptomatic recurrent pericarditis at the American Heart Association Scientific Sessions in November 2024. Findings indicated that CardiolRx significantly reduced pericardial pain in patients, with most experiencing relief within 5 days, and that the benefits were sustained over the extended 26 week study. The treatment also lowered inflammation and prevented recurring episodes, leading to a significant decrease in pericarditis occurrences.

The biotech company is also developing CRD-38, a drug formulation of cannabidiol that is administered subcutaneously for treating heart failure.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Gold Mountain Limited (ASX: GMN) (“Gold Mountain” or “the Company” or “GMN”) is excited to announce it has received 224 soil samples from the southern section of the Salinas II Project in the Bananal Valley in Brazil. This new data has helped the team define a 14-hole drill program to test 10 high-priority lithium anomalies, some of which are coincident with outcrops of weathered pegmatite. The potential of this emerging Lithium district is highlighted by Latin Resources Collina Lithium Deposit (70.9Mt @ 1.25% Li2O), which lies along regional structural strike from GMN’s Salinas II Project.

Highlights

Work Undertaken

  • Assays received from 100 and 200 metre spaced soil sampling lines with soil samples taken at 50 metre intervals.
  • Lithium anomalies identified over the 1.5 km strike extent of the soil grid with coincident Be, Rb, Sn and Tl anomalies.
  • No lithium anomalies found in areas of laterite however tin anomalies as well as quartz and tourmaline occurrences suggest pegmatite extensions under the laterite.
  • Drill holes defined so environmental permits can be obtained to allow drilling to take place.

Future Workplan

  • Obtain environmental permits for drilling
  • Extra soil lines in the NW of tenement to follow up anomalies previously defined
  • Continue detailed mapping to refine currently identified pegmatite trends
  • Drilling of the lithium targets identified.

Details

Results from exceptionally high value stream sediment sample have been followed up with soil samples and grid based mapping in the southern part of 831.700/2022 and drilling targets had been identified.

Mapping prior to and during soil sampling identifies numerous small pegmatites and some larger pegmatites to a maximum of 10 metres wide. Areas of large quartz boulders, possibly quartz cores to pegmatites, were also mapped and in places are coincident with lithium and lithium pathfinder anomalies. Pegmatites cross cut and are younger than the foliation in the host G3 type granite.

Regional structure from geophysics and from topography shows a strong NE to ENE trend, subparallel to the Latin Resources “Lithium Corridor.” Drilling will be oriented at 90 degrees to the regional trend initially, as the most probable major pegmatite orientation direction.

Strong vertical zonation in the lithium pegmatite geochemical responses are present and close attention to the location of laterite and the old lateritised surface is critical to interpretation of where lithium pegmatites may be concealed by leaching of lithium.

Drill targets were defined by lithium anomalies and by occurrences of pegmatite or extensive float of pegmatite minerals, lithium pathfinder elements, large quartz boulders or anomalous quartz concentrations.

The lateritic weathering zone is estimated from mapping to be up to 50 metres thick within the tenement, but locally may be significantly thicker. Drilling below this weathered layer is essential to get analyses that reflect the actual grade of any pegmatites present. Within the weathering zone low values of lithium are expected from potentially economic pegmatites.

Images & Maps

Figure 1 shows the location of the Salinas Project tenements in relation to Latin resources Collina deposit and to other tenements held by major explorers including Rio Tinto.

Mapping and soil sampling in the western Bananal Valley tenement, 831.700/2022, has defined areas of laterite as well as various larger pegmatite and quartz occurrences.

Figure 2 shows the extensive high order stream sediment target zones in the Bananal valley tenement, with their follow up soil lines and potential pegmatite mineral occurrences, including green tourmaline, indicating highly evolved pegmatites.

Lower order anomalies in the northeast are still considered highly prospective, with lower order results due to more intensive weathering and leaching of surface rocks.

Click here for the full ASX Release

This post appeared first on investingnews.com

Bitcoin adoption is gaining traction as several US states propose measures to establish strategic reserves.

The trend stems from broader discussions spearheaded recently by incoming President Donald Trump and his allies, who are advocating for a federal plan to establish a strategic Bitcoin reserve.

The price of Bitcoin hit new all-time highs in 2024, sparking attention from state lawmakers interested in its potential to serve as a hedge against inflation and economic instability. Since Bitcoin surpassed the US$106,000 threshold in December, several states have put forth legislation to get exposure to the popular digital asset.

Currently, five states — Texas, Pennsylvania, Ohio, New Hampshire and North Dakota — are actively considering proposals to incorporate Bitcoin into their financial systems. Here’s an overview of the initiatives underway.

1. Texas

Texas has taken significant steps toward adopting a strategic Bitcoin reserve.

In December of last year, Republican Representative Giovanni Capriglione introduced a bill proposing the establishment of a strategic Bitcoin reserve for the state. The legislation mandates that any Bitcoin acquired must remain in cold storage for at least five years, ensuring security and long-term value retention.

The proposal also includes a mechanism that would allow Texans to donate to the state’s Bitcoin fund, building on public interest in digital asset adoption. Proponents argue that the reserve would enhance Texas’ financial stability while promoting innovation in the digital asset sector.

2. Pennsylvania

This past November, Pennsylvania lawmakers proposed a bill that would enable the state to allocate up to 10 percent of its general, emergency and state investment funds to Bitcoin. If enacted, the measure could lead to nearly US$1 billion worth of Bitcoin being added to Pennsylvania’s reserves, based on current valuations.

3. Ohio

Ohio’s legislative efforts began on December 17, when Republican Representative Derek Merrin introduced the Ohio Bitcoin Reserve Act. The new legislation would establish a Bitcoin fund within the state treasury, granting the Ohio treasurer discretion over the purchase and management of the asset.

‘Ohio must embrace technology and protect our tax revenue from erosion,” Merrin said in a tweet.

4. New Hampshire

On January 10, New Hampshire Republican Representative Keith Ammon proposed a bill aimed at diversifying the state’s holdings by allowing investment in both precious metals and digital assets.

Although Bitcoin is not explicitly mentioned in the bill, its market dominance makes it a likely candidate for inclusion.

The proposal outlines requirements for secure storage and qualified custodians. It also permits the state treasury to engage in lending or staking activities, reflecting a more expansive approach to digital asset utilization.

Ammon has underscored the importance of early adoption, saying, “The state that is last to build a Bitcoin reserve will lose. It’s urgent that states act sooner than later, and that takes some education on the part of state officials.’

5. North Dakota

North Dakota’s approach began with a resolution introduced on January 10, encouraging the state to invest a portion of its funds in digital assets and precious metals. While the resolution is less specific than formal legislation, it represents a step toward exploring Bitcoin’s potential role in the state’s treasury.

Lawmakers are expected to refine the proposal and potentially draft comprehensive legislation in the coming months.

Investor takeaway

Tim Kravchunovsky, CEO of decentralized telecommunications network Chirp, noted that these developments could have far-reaching effects in encouraging other states to follow suit.

“The increasing number of US states considering adding Bitcoin to their reserves is bound to put pressure on the states that are lagging behind on innovation,” he explained.

Kravchunovsky added that growing interest in Bitcoin among US states mirrors global trends, with countries such as Brazil and Hong Kong reportedly considering similar measures.

“Not only will this rising tide eventually push other US states to introduce their own Bitcoin bills, but we’re already seeing a sense of FOMO across the globe,” he noted.

As Trump prepares for his inauguration, investors anticipate that his administration will continue to explore policies that could integrate cryptocurrencies into federal financial systems.

Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Pharmaceutical giant Johnson & Johnson (J&J) (NYSE:JNJ) has announced plans to acquire Intra-Cellular Therapies (NASDAQ:ITCI) in a US$14.6 billion deal, marking the largest acquisition for the sector in over two years.

The purchase, which is expected to close later this year pending regulatory and shareholder approvals, will give J&J access to Intra-Cellular’s portfolio of treatments for neuropsychiatric and neurodegenerative disorders.

This includes Caplyta (lumateperone), an oral therapy for schizophrenia and bipolar depression that has been approved by the US Food and Drug Administration. Net product sales for Caplyta came in at US$175.2 million in the Q3 2024, a 39 percent increase year-on-year, with Intra-Cellular raising its annual guidance to US$665 million to US$685 million.

The move will strengthen J&J’s focus on treatments for brain disorders, aligning with its long-term strategy of enhancing its pharmaceutical business following the 2023 spinoff of its consumer health division.

J&J has agreed to pay US$132 per share in cash for Intra-Cellular, representing a 39 percent premium over the company’s closing share price before the announcement. Intra-Cellular rose by 34 percent in response to the news on Monday (January 13), while shares of J&J experienced a modest 1.5 percent gain that day.

Joaquin Duato, J&J’s CEO, emphasized to shareholders that the deal will enhance the company’s ability to deliver transformative treatments for neuropsychiatric and neurodegenerative disorders.

“Building on our nearly 70-year legacy in neuroscience, this unique opportunity to add Intra-Cellular Therapies to our Innovative Medicine business demonstrates our commitment to transforming care and advancing research in some of today’s most devastating neuropsychiatric and neurodegenerative disorders,” he said a press release.

Caplyta stands out for its safety and efficacy profile, with ongoing Phase 3 trials exploring its potential in major depressive disorder (MDD) and bipolar mania. If approved for MDD, Caplyta could become a standard of care, filling a gap in treatment options for one of the most prevalent mental health conditions globally.

In addition to Caplyta, J&J will gain access to Intra-Cellular’s pipeline, which includes ITI-1284, a Phase 2 drug candidate targeting generalized anxiety disorder and Alzheimer’s-related psychosis.

J&J is scheduled to provide further financial details during its Q4 earnings call on January 22.

Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com